Sept. 14, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that following a hearing on September 12, 2008, the U.S. Court of Appeals for the District of Columbia has vacated an April 2008 ruling, which granted Teva 180-day exclusivity for its Risperidone Tablets, AB-rated to Janssen's Risperdal(R) Tablets. As a result of this decision, the U.S. Food and Drug Administration is no longer enjoined from approving subsequent Abbreviated New Drug Applications (ANDA).
The details can be read here.
No comments:
Post a Comment